Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
May 20 2021 - 4:05PM
Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board
of Directors
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
company with a robust pipeline of investigational therapeutics
built on protein dysregulation expertise, announced today the
appointment of Sanjiv K. Patel, MBBS, MA, MBA, to its
Board of Directors.
“Sanjiv is an experienced leader with
significant industry experience that uniquely positions him to
guide us as we look towards transitioning to a fully integrated
research, development and commercial biotechnology company,”
commented Lars Ekman, MD, PhD, Prothena’s Chairman. “We welcome
Sanjiv to our Board and look forward to his contributions in
advising Prothena during this transformational period.”
“I’m excited to join the Board at this pivotal
stage for Prothena. The Company’s leading protein dysregulation
expertise is clearly reflected in its robust and promising pipeline
of novel programs in areas of high unmet need,” said Dr. Patel. “I
look forward to working with the Prothena team to contribute
strategically to the Company’s continued growth.”
Sanjiv K. Patel, MBBS is President, Chief
Executive Officer, and a member of the board of Relay Therapeutics,
a clinical-stage precision medicine company. Before joining Relay
Therapeutics, Dr. Patel served in various roles at Allergan, Inc.
for over a decade. He most recently served as Allergan’s Executive
Vice President, Chief Strategy Officer and previously as Corporate
Vice President, Global Strategic Marketing and Global Health
Outcomes. Prior to this, he was a management consultant at The
Boston Consulting Group and practiced as a surgeon within the UK’s
National Health Service.
Dr. Patel earned his MBBS from University of
London, his MA in Medical Sciences from the University of
Cambridge, his MRCS from the Royal College of Surgeons of England,
and his MBA from INSEAD.
About Prothena
Prothena Corporation plc is a late-stage
clinical company with a robust pipeline of novel investigational
therapeutics, built on protein dysregulation expertise, with the
potential to change the course of devastating rare peripheral
amyloid and neurodegenerative diseases. Fueled by its deep
scientific expertise built over decades of research, Prothena is
advancing a pipeline of therapeutic candidates for a number of
indications and novel targets for which its ability to integrate
scientific insights around neurological dysfunction and the biology
of misfolded proteins can be leveraged. Prothena’s pipeline
includes both wholly-owned and partnered programs being developed
for the potential treatment of diseases including AL amyloidosis,
ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a
number of other neurodegenerative diseases. For more information,
please visit the Company’s website at www.prothena.com and follow
the Company on Twitter @ProthenaCorp.
Investors & MediaJennifer Zibuda, Director,
Investor Relations &
Communications650-837-8535, jennifer.zibuda@prothena.com
Prothena Corp. Plc - Ordinary Shares (MM) (NASDAQ:PRTAV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Prothena Corp. Plc - Ordinary Shares (MM) (NASDAQ:PRTAV)
Historical Stock Chart
From Jul 2023 to Jul 2024